信達國際控股(00111.HK)擬購買票據 總代價4954萬港元
格隆匯2月11日丨信達國際控股(00111.HK)發佈公告,2020年2月11日,公司已於公開市場購買(i)於2021年1月23日到期的本金總額合計約220萬美元(相當於約1716萬港元)8.75%建業票據及(ii)於2021年11月8日到期的本金總額約200萬美元(相當於約1560萬港元)6.75%建業票據,總代價為約429萬美元(相當於約3347萬港元)。
同日,公司已於公開市場購買於2022年6月27日到期的本金總額約200萬美元(相當於約1560萬港元)7.5%合生票據,總代價為約206萬美元(相當於約1607萬港元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.